Regeneron Shuts Down Respiratory Syncytial Virus Drug After Phase 3 Trial Fails

Regeneron Pharmaceuticals announced it would discontinue development of its respiratory syncytial virus drug following the failure of a Phase 3 study.

Suptavumab did not meet the trial’s primary endpoint for signs of efficacy in a subgroup of patients, with adverse events roughly equal between the drug and the placebo. The company assessed the endpoint through day 150 of treatment.

Regeneron executives expressed disappointment, but noted the company “has a robust pipeline across many serious diseases.”